Quisinostat
Quisinostat (USAN; development code JNJ-26481585) is an experimental drug candidate for the treatment of cancer.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Quisinostat (USAN; development code JNJ-26481585) is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity. It is highly potent against class I and II HDACs. __TOC__
Clinical trials
Results of a phase I trials in patients with multiple myeloma in combination with bortezomib and dexamethasone were published in 20161.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1329688884 under CC BY-SA 4.0; modifications have been made.
References
- ↩Wikipedia “Quisinostat” publication date (×1) · confidence 0.95 revision URL